DRY EYE SYNDROME TREATMENT MARKET ANALYSIS

Market Challenges And Opportunities

Global Dry Eye Syndrome Treatment Market - Drivers

Increasing organic strategies such as the U.S. Food and Drug Administration approval is expected to propel growth of the global dry eye syndrome treatment market during the forecast period. For instance, in October, 2022, Novaliq, a biopharmaceutical company focusing on ocular therapeutics, announce the approval of New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for CyclASol (cyclosporine ophthalmic solution), an anti-inflammatory product for the treatment for the signs and symptoms of dry eye disease (DED).

Furthermore, key companies focusing on product launch of dry eye syndrome treatment are expected to propel growth of the global dry eye syndrome treatment market during the forecast period. For instance, in January 2022, Sun Pharmaceutical Industries, Inc., one of the global specialty generic pharmaceutical company, announced the launch of CEQUA (cyclosporine ophthalmic solution 0.09% w/v), a calcineurin inhibitor immunomodulator indicated to increase tear production in patients with moderate to severe keratoconjunctivitissicca (dry eye).

Global Dry Eye Syndrome Treatment Market: Restraint

The major factors that hinder growth of the global dry eye syndrome treatment include the lack of awareness of dry eye syndrome in emerging country such as Saudi Arabia. For instance in January 2021, a research article was published by International Journal of Medicine in Developing Countries, according to which a there is lack of awareness of dry eye syndrome among the Saudi Arabian population most of the people did not have routine ophthalmologist visits and tended

to use electronic devices for a long time without a break knowing the risk infecting with dry eye syndrome.